{"name":"Jiangsu Sinorda Biomedicine Co., Ltd","slug":"jiangsu-sinorda-biomedicine-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"X842","genericName":"X842","slug":"x842","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"X842","genericName":"X842","slug":"x842","phase":"phase_3","mechanism":"X842 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOS2dmTGkwQ05IOHJLX1RVeEppWlNYTEx0aDhpRU9Vd3c2ejk1S0duSVhFYjhUZlUta3pwQVRIbnVyQW53MXlCOFNYVXdNdjhFSkdjbEpialhaaFh3dXR6cGZWeGhEMTZYQnB2VFdYOVczcEVBV01BZjN0RHVVQU5Hak9CWjZxQXNLeVdkenllOTA2bUItcmdCR2J2NGFtd0Q0VURkam5iellRZzFiUnMyemkwRWJuX3hxYmNXTW1OYkQzMGtaVTllXzRlQU5MTG5oeFRVNEpTRmtCSmFTbVEyNVBaUldXWXB3c0JWdHNJMms0MHR3Z21kRW9B?oc=5","date":"2024-12-04","type":"regulatory","source":"Finansavisen","summary":"Linaprazan glurate receives marketing approval in China - Finansavisen","headline":"Linaprazan glurate receives marketing approval in China","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}